MedTrace Logo

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2017-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AC-170 0.24%

1 drop in each eye at 2 separate times during a 14 day period

DRUG

AC-170 0%

1 drop in each eye at 2 separate times during a 14 day period

Sponsors & Collaborators

  • Aciex Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Eugene McLaurin, MD · Total Eye Care, PA

  • Edward Meier, MD · Eye Care Associates of Greater Cincinnati

  • Mark Bergmann, MD · Eye Care Associates of Greater Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01881113 on ClinicalTrials.gov